Sign In
Buy L
$116.01
-0.360 (-0.309%)
At Close: Jul 31, 2026
DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced
LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK
02:23pm, Tuesday, 13'th May 2025
NEW YORK , May 13, 2025 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable June 10, 2025 to s
LOEWS CORPORATION REPORTS NET INCOME OF $370 MILLION FOR THE FIRST QUARTER OF 2025
06:00am, Monday, 05'th May 2025
5.1 MILLION COMMON SHARES REPURCHASED IN 2025 FOR $429 MILLION NEW YORK , May 5, 2025 /PRNewswire/ -- Loews Corporation (NYSE: L) today released its first quarter 2025 financial results. First Quarter
Loews Corporation to Release First Quarter 2025 Results on May 5, 2025
10:00am, Tuesday, 15'th Apr 2025
NEW YORK , April 15, 2025 /PRNewswire/ -- Loews Corporation (NYSE: L) will report first quarter 2025 financial results on Monday, May 5, 2025. On that date the Company will also post earnings remark
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
04:05pm, Thursday, 27'th Mar 2025
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing –
Loews: At $87 It's Undervalued Given Management's Persistent History Of Success
04:33pm, Tuesday, 11'th Feb 2025
Loews: At $87 It's Undervalued Given Management's Persistent History Of Success
LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK
12:16pm, Tuesday, 11'th Feb 2025
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable March 11, 2025 to
LOEWS CORPORATION REPORTS NET INCOME OF $187 MILLION FOR THE FOURTH QUARTER OF 2024 AND $1,414 MILLION FOR THE FULL YEAR
06:00am, Monday, 10'th Feb 2025
7.7 MILLION COMMON SHARES REPURCHASED IN 2024 FOR $611 MILLION NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Loews Corporation (NYSE: L) today released its fourth quarter 2024 financial results. Fourth Qu
Loews Corporation to Release Fourth Quarter 2024 Results on February 10, 2025
10:00am, Tuesday, 21'st Jan 2025
NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Loews Corporation (NYSE: L) will report fourth quarter 2024 financial results on Monday, February 10, 2025. On that date the Company will also post earnings
HONG KONG , Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK1
LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK
11:24am, Tuesday, 12'th Nov 2024
NEW YORK , Nov. 12, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable December 10, 2024
LOEWS CORPORATION REPORTS NET INCOME OF $401 MILLION FOR THE THIRD QUARTER OF 2024
06:00am, Monday, 04'th Nov 2024
NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) today released its third quarter 2024 financial results. Third Quarter 2024 highlights: Loews Corporation reported net income of $40
Loews Corporation to Release Third Quarter 2024 Results on November 4, 2024
10:00am, Tuesday, 15'th Oct 2024
NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) will report third quarter 2024 financial results on Monday, November 4, 2024. On that date the Company will also post earnings r
Loews Arlington Selects ROH to Streamline Sales Operations and Payment Processing
09:47am, Thursday, 03'rd Oct 2024
NEW YORK--(BUSINESS WIRE)-- #SaaS--ROH, the hospitality industry's first payments and revenue management platform designed to help hotels increase profitability, today announced that Loews Arlington h
FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
01:00am, Friday, 13'th Sep 2024
Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), t
